What diseases does Vismodegib treat?

Vismodegib (Vismodegib) is approved for the treatment of metastatic and locally advanced basal cell carcinoma that is not treatable with surgery or radiation therapy at a dose of 150 mg orally once daily until disease progression or unacceptable toxicity. As the drug has become more readily available and a range of side effects have been noted, including secondary tumor formation, neoadjuvant vismodegib is recommended and appears to reduce surgical defect size after 3 months or more for non-recurrent basal cell carcinoma in functionally sensitive sites.

Vimodegib is an oral drug designed to selectively inhibit abnormal signaling in the Hedgehog(Hh) pathway, a potential molecular driver of BCC. Vimodegib binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signaling. The Hh pathway promotes cell development and division of several cell types through direct cell activation and secondary activation of multiple pathways of tissue generation, including angiogenesis (new blood vessel formation) and tissue growth. The Hh pathway is often overactivated in BCC through downregulation of Hedgehog signaling inhibition.

The original drug of Vimodegib is not currently on the market in the country, so it cannot be included in medical insurance. Overseas, Vimodegiboriginal drug has Turkish version and European version, specificationsThe price of 150mg*28 capsules per box may be around RMB 10,000-30,000 (the price may fluctuate due to the exchange rate). The price is very expensive, and there are currently no generic versions of Vimodegib. For more drug information and specific prices, please consult Yaodei Medical Consultants.